1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
China Isotope & Radiation Corporation

China Isotope & Radiation Corporation

1763.HK
China Isotope & Radiation CorporationHK flagHong Kong Stock Exchange
17.05
HKD
-0.11
- -
5.45BMarket Cap
China Isotope & Radiation Corporation
1763.HK
(Hong Kong Stock Exchange)

Recent

price

17.05

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
6.73
7.39
11.14
11.64
12.47
13.36
16.08
19.24
20.74
23.68
22.47
Revenue per Share
0.79
0.82
1.13
1.15
1.03
0.67
1.05
1.23
1.16
1.27
1.02
Basic EPS, GAAP
1.22
1.43
1.79
2.06
1.88
0.91
2.48
2.7
0.27
0.45
1.68
Free Cash Flow per Basic Share
- -
1
0.74
0.32
0.31
0.14
0.18
0.38
0.44
0.39
0.39
Dividend per Share
0.63
0.63
1
1.15
1
1
1
1
1
1
1
Book Value per Share
4.05
4.37
10.04
14.93
15.17
16.61
18.24
20.06
21.4
22.95
23.79
Tangible Book Value per Share
320
320
240
279
320
320
320
320
320
320
320
Basic Weighted Avg Shares
2,152
2,363
2,672
3,250
3,989
4,274
5,144
6,154
6,635
7,575
7,188
Sales/Revenue/Turnover
20.8
20.36
18.97
18.28
16.06
13.87
14.42
14.56
12.13
14.59
14.59
Operating Margin (%)
54
65
68
74
132
172
197
223
264
245
265
Depreciation Expense
254
262
271
322
329
214
336
392
371
407
327
Net Income, GAAP
15.53
15.26
14.75
15.23
14.84
20.24
16.15
17.98
15.86
15.85
33.82
Effective Tax Rate (%)
11.81
11.09
10.16
9.91
8.25
5
6.53
6.37
5.59
5.37
4.56
Profit Margin (%)
704
622
1,544
2,692
2,711
2,999
2,642
3,512
3,941
3,895
4,045
Working Capital
60
- -
150
150
655
630
185
838
1,478
1,601
1,802
LT Debt
1,354
1,473
2,446
4,338
5,003
5,506
6,034
6,610
7,139
7,745
8,133
Total Equity
- -
23.24
18.31
13.76
10.24
7.63
9.32
10
8.1
9.54
6.44
Return on Invested Capital (%)
- -
10.14
6.67
5.56
2.62
-0.8
0.99
1.82
-0.1
-0.51
0.58
Return on Capital (%)
- -
131.05
123.41
115.01
102.86
66.77
104.96
122.63
115.97
127.13
102.36
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.82%
8.13%
5.02%
Free Cash Flow
43.45%
87.23%
277.83%
Net Income, GAAP
5.11%
11.75%
-19.48%
Sales/Revenue/Turnover
13.12%
11.37%
-5.11%
Total Cash Common Dividend
- -
28.92%
1.09%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
6,635
2024
- -
- -
- -
- -
7,575
2025
- -
- -
- -
- -
7,188

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1.16
2024
- -
- -
- -
- -
1.27
2025
- -
- -
- -
- -
1.02

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.44
2024
- -
- -
- -
- -
0.39
2025
- -
- -
- -
- -
0.39
Similar Companies
UFP Technologies, Inc. (UFPT)
TriSalus Life Sciences, Inc. (TLSI)
StatSure Diagnostic Systems, Inc. (SSUR)
Nihon Kohden Corporation (NHNKF)
Allgens Medical Technology Co. Ltd. (688613.SS)
TaiDoc Technology Corporation (4736.TWO)
Business
China Isotope & Radiation Corporation (CIRC), a holding subsidiary of China National Nuclear Corporation founded in 1983 and headquartered in Beijing, China, ranks as China's largest comprehensive nuclear enterprise focused on the research, development, manufacture, distribution, and service of radioisotope and radiation technology products; its core offerings encompass over 70 nuclides and 300 products across radioisotope preparation via nuclear reactors and cyclotrons, diagnostic and therapeutic radiopharmaceuticals including 99Mo-99mTc generators and 99mTc kits, radioactive sources, radiation engineering solutions such as nuclear reactors and cobalt-60 facilities, irradiation processing services for medical devices, food, and traditional Chinese medicines, in vivo therapy nuclides, radioimmunoassay kits, and [13C]/[14C]-urea breath test kits and instruments; operations span three radiopharmaceutical manufacturing and research bases in Beijing, Chengdu, and Shenzhen, with radiopharmacies in approximately 20 cities supporting a nationwide marketing and technical network, alongside exports of seven product categories to over 50 countries, primarily targeting healthcare, industrial, and research sectors in Asia and globally. CIRC maintains one of the world's widest ranges of isotope products and the most complete industrial chain in its field, positioning it as Asia's largest supplier of nuclear technology applications. In late November 2025, CIRC entered a strategic cooperation agreement with CNNC Capital Holdings Limited to collaborate on mergers and acquisitions, equity investments, and resource sharing for enhanced development in the nuclear sector; the company also received recognition for its ESG practices, winning the Outstanding China ESG Practice (2025) award and inclusion in the ESG Pioneers Index (Top 100) by Central China Securities.